<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00989469</url>
  </required_header>
  <id_info>
    <org_study_id>NEXIRI</org_study_id>
    <nct_id>NCT00989469</nct_id>
  </id_info>
  <brief_title>Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation</brief_title>
  <acronym>NEXIRI</acronym>
  <official_title>SORAFENIB (NEXAVAR®) in Combination With Irinotecan in the Second Line Treatment or More of Metastatic Colorectal Cancer With K-RAS Mutation : a Multicentre Two-part Phase I/II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre two-part phase I/II study evaluating response and safety of SORAFENIB in&#xD;
      combination with irinotecan in the second line treatment or more of metastatic colorectal&#xD;
      cancer with K-RAS mutation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease control</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events by using the NCI-CTCAE version 3 scale</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Sorafenib and irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexavar (Sorafenib) and irinotecan (Campto)</intervention_name>
    <description>Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion</description>
    <arm_group_label>Sorafenib and irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Histologically proven adenocarcinoma of the colon or rectum asymptomatic primary&#xD;
             tumour or surgically removed mCRC patients with previously unresectable metastatic&#xD;
             disease&#xD;
&#xD;
          -  Patient with at least one tumoral lesion: measurable in a unidimensional way with a&#xD;
             spiral scanner according to RECIST, no previous irradiation in this area&#xD;
&#xD;
          -  Disease progression after irinotecan-based chemotherapy&#xD;
&#xD;
          -  Disease progression after one or more previous lines of chemotherapy received in&#xD;
             metastatic situation&#xD;
&#xD;
          -  WHO &lt;= 2&#xD;
&#xD;
          -  Patient having a mutated KRAS on 12 or 13 codons on the primary tumour or a metastasis&#xD;
&#xD;
          -  Adequate liver function : Bilirubin ≤ 1,5 x UNL, ASAT ou ALAT ≤ 2,5 x UNL (or &lt; 5 x&#xD;
             UNL for subjects having a hepatic insufficiency in connection with hepatic metastases)&#xD;
&#xD;
          -  Polynuclear neutrophils ≥ 1 500/mm3&#xD;
&#xD;
          -  Haemoglobin &gt; 10g/dl&#xD;
&#xD;
          -  Platelets ≥ 100 000/mm3&#xD;
&#xD;
          -  Amylase and lipase &lt; 1,5 x UNL&#xD;
&#xD;
          -  Serum Creatinin &lt; 1,5 x UNL&#xD;
&#xD;
          -  Adapted contraceptive measures during treatment and continued at least three months&#xD;
             after end of the treatment&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Affiliated to or benefiting from health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gilbert's disease&#xD;
&#xD;
          -  Brain metastases or carcinomatous symptomatic meningitis&#xD;
&#xD;
          -  Exclusive bone metastasis&#xD;
&#xD;
          -  Previous cancers not considered as cured in the 5 years before inclusion (except for&#xD;
             baso-cellular skin carcinoma) Surgery (except diagnostic biopsy) or radiotherapy&#xD;
             within 4 weeks before inclusion&#xD;
&#xD;
          -  Disorders of the cardiac rhythm requiring an anti-asynchronous treatment (except beta&#xD;
             blockers or digoxine within the framework of a chronic auricular fibrillation),&#xD;
             unstable coronaropathy or myocardial infarction &lt; 6 months, congestive cardiac failure&#xD;
             &gt; Rank II NYHA (Grade 2), uncontrolled arterial hypertension&#xD;
&#xD;
          -  Previous epilepsy crises requiring long term antiepileptic treatment Previous organ&#xD;
             transplant requiring immunosuppressor treatment Severe bacterial or fungus infection&#xD;
             (&gt; Grade 2 NCI CTC version 3) Known HIV Infection&#xD;
&#xD;
          -  Long term treatment by known inductors of the CYP 3A4 like Rifampicin, Millepertuis&#xD;
             (hypericum perforatum), Phenytoin, Carbamazepin, Phenobarbital, Dexamethasone et&#xD;
             Ketonazole&#xD;
&#xD;
          -  Known allergy to one of the therapeutic agents&#xD;
&#xD;
          -  Reasons (psychological, family, social or geographical) that could compromise the&#xD;
             participation of the patient in the study&#xD;
&#xD;
          -  Intestinal malabsorption or gastro-intestinal surgery being able to affect Sorafenib&#xD;
             absorption. Occlusive or sub-occlusive syndrome.&#xD;
&#xD;
          -  Dysphagic patient or patient not being able to take treatment by orally inflammatory&#xD;
&#xD;
          -  Chronic digestive disease involving chronic diarrhoea (NCI N+Bethesda &gt;= 1.2g)&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days before the start of this study&#xD;
&#xD;
          -  Other concomitant experimental drugs or other concomitant anticancer agents (except&#xD;
             Irinotecan and Sorafenib)&#xD;
&#xD;
          -  Medical or psychological state that in the opinion of the investigator will not allow&#xD;
             the patient to terminate the study or to understand and sign the informed consent form&#xD;
&#xD;
          -  Pregnancy and breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmannuelle SAMALIN-SCALZI, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRLC Val d'Aurelle-Paul Lamarque</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debre</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 2, 2009</study_first_submitted>
  <study_first_submitted_qc>October 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2009</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

